Skip to main content
Premium Trial:

Request an Annual Quote

NimbleGen Secures Additional $1.5M in Series B Round

NEW YORK, Oct. 17 – NimbleGen Systems has added $1.5 million in a second closing of its Series B financing round, the company said on Wednesday. A $9 million first closing was announced on Sept. 11, and the recent cash infusion brings to $14 million NimbleGen’s total funds raised to date.

NimbleGen, based in Madison, Wis., produces custom high-density DNA microarrays and is developing a desktop DNA microarray synthesizer based on its proprietary maskless array synthesizer technology, according to the company. MAS uses digital light processors to synthesize oligonucleotides in situ, the firm said.

In an e-mail this week, Mike Treble, NimbleGen’s CEO, said the company had begun shipping its arrays to collaborators. Last week he said NimbleGen expects to start delivering the first synthesizers within 18 months.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.